Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)
Authors:
Top Cited Papers
- 5 June 2026
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 407 (10546) , 2375-2386
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- American Association of Kidney Patients
This publication has 24 references indexed in Scilit:
- Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 DiabetesJACC, 2025
- Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF TrialEuropean Journal of Heart Failure, 2025
- Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trialNature Medicine, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonistsDiabetologia, 2023
- A meta-analysis of GFR slope as a surrogate endpoint for kidney failureNature Medicine, 2023
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- Renal Tubular Acidosis and Management Strategies: A Narrative ReviewAdvances in Therapy, 2020
- KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2020
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004